In a pemetrexed-resistant NSCLC cell line PC-9/PEM, which also acquired EGFR-TKI resistance, FAK was hyperphosphorylated and a combination of FAK inhibitor and osimertinib recovered EGFR-TKI sensitivity32. The gene discussed is PTK2; the disease is non-small cell lung carcinoma.